<DOC>
	<DOCNO>NCT01784757</DOCNO>
	<brief_summary>A study investigate two different tablet formulation ODM-201 best suit use development compound treatment metastatic chemotherapy-naive castration-resistant prostate cancer . Patients successfully complete bioavailability study able receive treatment current capsule formulation ODM-201 progression disease safety tolerability ODM-201 assess throughout .</brief_summary>
	<brief_title>Bioavailability Study ODM-201 Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Written inform consent ( IC ) obtain . Histologically confirm adenocarcinoma prostate Progressive metastatic disease Ongoing androgen deprivation therapy luteinising hormonereleasing hormone ( LHRH ) analogue antagonist bilateral orchiectomy Adequate bone marrow , hepatic renal function Able swallow ODM201 whole capsule tablet . Previous chemotherapy prostate cancer . Known metastasis brain . History malignancy within previous 5 year , except basal cell carcinoma skin . Known gastrointestinal condition significantly affect absorption study treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>